메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Renalys Pharma Announces Support for Alport Syndrome Registry Study Organized by Japanese Society for Pediatric Nephrology

TOKYO, Oct. 22, 2025 -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") is pleased to announce the company is providing financial support for the Alport Syndrome Registry Study organized by the Japanese Society for Pediatric Nephrology (Head Office: Chiyoda-ku, Tokyo). The study is headed by Professor Kandai Nozu, Department of Pediatrics, Graduate School of Medicine, Kobe University. Renalys will provide research funding for this initiative but will not be involved in the study's undertaking, data analysis, or publication. Speaking on the announcement, Profess
- 김갑성 기자
- 2025-10-22 14:00
ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors

SINGAPORE, Oct. 22, 2025 -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase 1 study of ACM-CpG, a TLR9 agonist formulated with ACM's proprietary polymersome platform through a strategic collaboration with the National Cancer Centre Singapore (NCCS). Preclinical experiments show that the ACM nanoparticle formulation fundamentally alters CpG's mechanism of action, enabling myeloid modulation through comprehensive TLR9 engagement in immunologically
- 김갑성 기자
- 2025-10-22 14:00
ACM 바이오랩스, 진행성 고형암 환자 대상 ACM-CpG 근육 내 투여에서 양호한 안전성 실마리정보 및 초기 약력학 결과 보고

[ 메디채널 김갑성 기자 ] 싱가포르 2025년 10월 22일 -- 차세대 나노입자 기반 면역치료제를 개발 중인 임상단계 바이오테크 기업 ACM 바이오랩스(ACM Biolabs)가 싱가포르 국립암센터(NCCS)와의 전략적 협력을 통해 ACM의 독자적 폴리머솜(polymersome) 플랫폼으로 제형화된 TLR9 작용제 ACM-CpG를 대상으로 진행 중인 1상 임상시험에서 얻은 고무적인 초기 임상 결과를 발표했다. 전임상 실험 결과, ACM 나노입자 제형은 CpG의 작용기전을 근본적으로 변화시켜 면역학적으로 '차가운' 종양에서 TLR9의 포괄적 관여를 통한 골수 조절을 가능케 하는 것으로 나타났다. 진행 중인 1상 임상시험(NCT06587295)[i]은 현재 싱가포르 국립암센터에서 ACM-CpG의 안전성, 내약성 및 약력학적 효과를 평가하기 위해 진행성 고형암 환자를 등록 중이다. 초기 임상 데이터는 이러한 전임상 결과가 인간에게도 적용되고 있음을 보여준다. 진행성 고형암 환자에게 ACM-CpG를 근육 내 투여(CpG 0.25mg의 저용량으로 주 1회 또는 격주 투여)한 결과, 생체표지자 데이터를 통해 강력한 전신 면역 활성화 효과
- 김갑성 기자
- 2025-10-22 14:00
ACROBiosystems•파트너사, 베이징 OrganoAsia 2025 성공적 폐막

[ 메디채널 김갑성 기자 ] 오가노이드 연구 및 상용화 촉진을 위해 중국, 일본, 한국의 주요 과학자들이 한자리에 서울, 한국 2025년 10월 22일 -- 아크로바이오시스템(ACROBiosystems)은 라이카 바이오시스템즈(Leica Biosystems), 몰레큘러 디바이스(Molecular Devices), 라이카 마이크로시스템즈(Leica Microsystems)와 공동으로 베이징에서 '오가노아시아 2025 - 오가노이드 과학의 최전선(OrganoAsia 2025-The Frontier of Organoid Science)' 를 개최했다. 이번 컨퍼런스는 오프라인 개막 세션과 실시간 온라인 중계를 결합한 하이브리드 방식으로 진행되었으며, 중국, 일본, 한국을 비롯한 전 세계 500명 이상의 전문가와 연구자가 참석하여 정밀의학, 신약 개발, 재생의학 분야에서 오가노이드 기술의 최신 동향과 미래 방향에 대해 논의했다. 전문가 전망: 연구•산업 응용 분야의 광범위한 진전 이번 컨퍼런스에는 아크로바이오시스템 부사장 로사나 장(Rosanna Zhang), 남방과학기술대 부교수 리량(Li Liang),
- 김갑성 기자
- 2025-10-22 10:48
Senna Wellness Retreat brings Mid-Autumn festival to 700 children in Sin Suoi Ho Commune, Lai Chau Province through the 'Trăng Lên Đỉnh Núi' campaign

BAC NINH, Vietnam, Oct. 22, 2025 -- Senna Wellness Retreat has successfully completed 'Trăng Lên Đỉnh Núi' (Moonrise over the mountain) campaign with a charitable trip to Sin Suoi Ho Commune, Lai Chau Province on October 02, 2025. The visit marked the completion of a two-month journey dedicated to bringing a meaningful Mid-Autumn Festival to children and local residents in Vietnam's northern highlands, reflecting Senna's commitment to give back to the community. Launched in August 2025, the campaign introduced the 'Về Nguồn' (Return to Roots) mooncake collection an
- 노기식 기자
- 2025-10-22 09:00
WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index

[ 메디채널 김갑성 기자 ] The only company from pharmaceutical industry selected for inclusion in the Index Also included in HSI ESG Index and Hang Seng ESG 50 Index Green CRDMO solution provider with outstanding sustainability performance HONG KONG, Oct. 22, 2025 -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced its inclusion in the 2025 Hang Seng Corporate Sustainability Benchmark Index. It stands out as the only company from the pharmaceutical industry selected for this prestigious recognition. The com
- 김갑성 기자
- 2025-10-22 08:30
Allianz Partners urges travellers to rethink coverage as new data shows Aussies still travelling uninsured

BRISBANE, Australia, Oct. 22, 2025 -- Allianz Partners is urging Australian travellers to rethink their approach to travel insurance, following new ICA and DFAT research revealing that one in seven travellers are still going overseas uninsured. The findings underscore Allianz Partners' ongoing commitment to helping Australians when things go wrong overseas. "It is concerning that those travellers who might decide against purchasing insurance are doing so because they think a destination is safe, because this doesn't give consideration to accidents, medical emergencies and
- 황정호 기자
- 2025-10-22 08:00
The Shaw Prize Award Presentation Ceremony 2025: Continuing 22 Years of Legacy in Science and Innovation

HONG KONG, Oct. 22, 2025 -- The Shaw Prize presented its awards to four 2025 Shaw Laureates on 21 Oct at the 2025 Award Presentation Ceremony, held in the Grand Hall of the Hong Kong Convention and Exhibition Centre. Approximately 600 guests from various sectors participated in the event. In his opening remarks, Professor Kenneth Young, Chair of The Shaw Prize Council, expressed deep sorrow at the passing of Professor Chen-ning Yang, a founding member of the Shaw Prize. Professor Young highlighted Professor Yang's pivotal role in shaping the Prize from its inception, and his pr
- 김갑성 기자
- 2025-10-22 01:17
AESOP Technology announces DxPrime is now a qualified solution on Mayo Clinic Platform

SAN FRANCISCO, Oct. 21, 2025 -- DxPrime, an AI-powered solution designed to enhance diagnostic accuracy through real-time integrity analysis and automated code translation, is now available on Mayo Clinic Platform. Driven by AESOP Technology's Clinical Deep Reasoning Network Model, DxPrime customizes its insights based on specialty, gender, and clinical context to ensure diagnostic completeness and precision. It delivers explainable, real-time diagnostic feedback and automatically converts diagnoses into medical codes to reduce misses, delays, or inaccuracies throughout the process fro
- 김갑성 기자
- 2025-10-21 23:30
Charming Medical Limited Announces Pricing of Initial Public Offering and Listing on Nasdaq

HONG KONG, Oct. 21, 2025 -- Charming Medical Limited (Nasdaq: MCTA) (the "Company"), a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products, today announced the pricing of its initial public offering (the "Offering") of 1,600,000 Class A ordinary shares, par value $0.0001 per share (the "Class A Ordinary Shares") at a price of $4.00 per share (the "Public Offering Price"). The Class A Ordinary Shares are expected to commence trading on the Nasdaq Capital Market on October 21, 2025, under the ticker symbol "
- 김갑성 기자
- 2025-10-21 23:00

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-11-04_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 04일 14시 40분